Zydus Pharmaceuticals has signed a license and supply agreement with CHEMI of Italy to launch the generic equivalent of Sanofi Aventis’s branded product Lovenox (enoxaparin sodium injection) in seven dosage strengths in the United States (US), the company informed in a statement.
It said that under the agreement, CHEMI will manufacture and supply the enoxaparin sodium injection, which Zydus will commercialise in the US. CHEMI owns proprietary rights on a pharmaceutical product composed of enoxaparin sodium (preservative-free) single-use pre-filled syringes, which is an AP-rated generic version of the branded product Lovenox.
CHEMI, utilising their proprietary technology, will produce the enoxaparin Sodium injection within proprietary manufacturing facilities located in Italy. CHEMI within ITF group is also vertically integrated on the enoxaparin sodium API manufacturing which ensures quality and an uninterrupted supply of the critical care product, the statement added.
Speaking on the development, Dr Sharvil Patel, Managing Director, Cadila Healthcare, said, “This partnership between Zydus and CHEMI is another step in our unwavering commitment to improve the supply of critical care drugs, which are vital in delivering quality patient care. In addition, this collaboration will bolster the Zydus’ injectable portfolio and demonstrates Zydus’ long-term commitment to drive growth through investment in complex generic products. We’re proud to be the first Indian company to launch a generic version of enoxaparin in the United States and are excited about this opportunity.”